In recent years, pharmacotherapy, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), one class of Obesity Management Medications (OMMs), has emerged as a potential treatment option or adjunct to MBS [9]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.